Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals Inc (NQ: DAWN )

13.37 +0.62 (+4.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,319,144
Open 12.76
Bid (Size) 13.44 (3)
Ask (Size) 14.50 (3)
Prev. Close 12.75
Today's Range 12.66 - 14.10
52wk Range 5.440 - 28.35
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What 8 Analyst Ratings Have To Say About Day One Biopharmaceutical
 
Via Benzinga
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via Globe NewsWire

Performance

YTD
-33.98%
-33.98%
1 Month
-27.34%
-27.34%
3 Month
-33.98%
-33.98%
6 Month
-33.35%
-33.35%
1 Year
+26.61%
+26.61%

More News

Read More
Day One to Participate in the Cowen 43rd Annual Health Care Conference
From Day One Biopharmaceuticals, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Where Day One Biopharmaceutical Stands With Analysts
Via Benzinga
What 7 Analyst Ratings Have To Say About Day One Biopharmaceutical
Via Benzinga
This Pediatric Cancer Company Makes It To Analyst's Conviction List
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
Via Benzinga
Day One Biopharmaceuticals Shares Jump As Pediatric Brain Cancer Candidate Shows Encouraging Responses
Via Benzinga
Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma
From Day One Biopharmaceuticals, Inc.
Via Globe NewsWire
Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
Via Benzinga
Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Via Benzinga
Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via Globe NewsWire
Day One Reports Third Quarter 2022 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via Globe NewsWire
Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)
From Day One Biopharmaceuticals, Inc.
Via Globe NewsWire
5 Value Stocks In The Healthcare Sector
Via Benzinga
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
Via FinancialNewsMedia
Exposures COVID-19
LegalZoom.com, Toast And Some Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Via Benzinga
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.